ORIGİNAL ARTICLE

C-Reactive Protein at 24 Hours after Hospital Admission may have Relevant Prognostic Accuracy in Acute Pancreatitis: A Retrospective Cohort Study

Filipe S. Cardoso, Leonel B. Ricardo, Ana M. Oliveira, David V. Horta, Ana L. Papoila, João R. Deus, Jorge Canena

Gastroenterology Department, Hospital Professor Doutor Fernando Fonseca, Amadora, Portugal

Biostatistics and Informatics Department, NOVA Medical School, NOVA University of Lisbon, Lisbon, Portugal

Received 26 October 2014; accepted 15 March 2015
Available online 19 April 2015

Abstract

Introduction: C-reactive protein (CRP) and Bedside index for Severity in Acute Pancreatitis (BISAP) have been used in early risk assessment of patients with AP.

Objectives: We evaluated prognostic accuracy of CRP at 24 hours after hospital admission (CRP24) for in-hospital mortality (IM) in AP individually and with BISAP.

Materials and Methods: This retrospective cohort study included 134 patients with AP from a Portuguese hospital in 2009–2010. Prognostic accuracy assessment used area under receiver–operating characteristic curve (AUC), continuous net reclassification improvement (NRI), and integrated discrimination improvement (IDI).

Results: Thirteen percent of patients had severe AP, 26% developed pancreatic necrosis, and 7% died during index hospital stay. AUCs for CRP24 and BISAP individually were 0.80 (95% confidence interval (CI) 0.65–0.95) and 0.77 (95% CI 0.59–0.95), respectively. No patients with CRP24 <60 mg/l died (P = 0.027; negative predictive value 100% (95% CI 92.3–100%)). AUC for BISAP plus CRP24 was 0.81 (95% CI 0.65–0.97). Change in NRI

Abbreviations: AP, acute pancreatitis; AUC, area under receiver–operating curve; BISAP, Bedside Index for Severity in Acute Pancreatitis; CECT, contrast enhanced computed tomography; CI, confidence interval; CRP, C-reactive protein; CRP24, C-reactive protein at 24 hours after hospital admission; IDI, integrated discrimination improvement; IM, in-hospital mortality; NRI, continuous net reclassification improvement; OR, odds ratio; SAP, severe acute pancreatitis; STROBE, Strengthening the Reporting of Observational Studies in Epidemiology.

* Corresponding author.

E-mail address: filipe.sousacardoso@hotmail.com (F.S. Cardoso).

http://dx.doi.org/10.1016/j.geja.2015.03.002

2341-4545/© 2015 Sociedade Portuguesa de Gastroenterologia. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Conclusions: CRP24 revealed good prognostic accuracy for IM in AP; its main role may be the selection of lowest risk patients.

© 2015 Sociedade Portuguesa de Gastrenterologia. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

The incidence of acute pancreatitis (AP) seems to be increasing in several countries.\textsuperscript{1,2} Most cases of disease follow a course without complications, but about 20% of patients develop severe AP (SAP).\textsuperscript{3} The overall mortality is 2.1–7.8%, but SAP leads to prolonged hospitalization and higher mortality.\textsuperscript{4,5}

The early risk assessment of patients with AP by accurate and reliable methods is necessary to improve clinical outcomes and reduce costs of treatment. Several tools for the early risk assessment of these patients have been developed; they include single biochemical markers, imaging methods, and complex scoring systems.\textsuperscript{6}

C-reactive protein (CRP) is an acute phase reactant that has been largely used in the early risk assessment of patients with AP. Among single biochemical markers, CRP remains the most useful in predicting SAP, especially due to its accuracy and accessibility.\textsuperscript{6,7} Despite these advantages, its prognostic accuracy has been validated for measurements no sooner than 36 hours after hospital admission.\textsuperscript{8,9} In this regard, some other tools for earlier risk assessment of patients with AP, such as Bedside Index for Severity in AP (BISAP), might be more useful.\textsuperscript{10}

BISAP has been validated as an accurate and reliable scoring system for early identification of patients with AP at risk for in-hospital mortality (IM).\textsuperscript{10–12} It comprises the assessment of 5 clinical variables in the first 24 hours after hospital admission: Blood urea nitrogen greater than 25 mg/dl; presence of impaired mental status on clinical evaluation; presence of systemic inflammatory response syndrome; age greater than 60 years; presence of pleural effusion on clinical or radiological evaluation. The index final score is calculated by adding one point per each variable present (out of 5 points). According to this scoring system, IM increases progressively with its final score, being 5–20% for a final score equal or greater than 3 points.\textsuperscript{10}

In this study, we hypothesized that CRP measured at 24 hours after hospital admission (CRP24) may have relevant prognostic value for IM in AP and this may add to the one from BISAP. Accordingly, we aimed to determine CRP24 individual prognostic accuracy for IM in AP and identify a clinically significant cutoff point; additionally, we sought to quantify the combined prognostic accuracy for IM in AP of CRP24 and BISAP.

2. Materials and Methods

The reporting of this study followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement.\textsuperscript{13} The local Health Research Ethics...
Board approved this study and the requirement for individual informed consent was waived.

2.1. Design, setting, participants, and data collection

This was a single center retrospective cohort study which included initially all patients consecutively admitted to the emergency department of a Portuguese general district hospital (Hospital Professor Doutor Fernando Fonseca, Amadora) with AP between January 2009 and December 2010. Of this set, patients with incomplete data on CRP24, BISAP score, or in-hospital final vital status were excluded.

Patients were identified from the hospital’s diagnostics dedicated computerized database. Demographic and clinical data were collected by 3 investigators from a variety of sources including patients’ charts (manual and electronic), laboratory reports, and radiology reports.

2.2. Operational definitions

The diagnosis of AP was made if 2 of the following 3 features were present: (i) Abdominal pain suggestive of AP; (ii) serum amylase and/or lipase activity at least 3 times greater than the upper limit of normal; and (iii) characteristic findings of AP on transabdominal ultrasonography or on contrast-enhanced computed tomography (CECT). Despite these criteria, all patients in whom the minimum 3-fold hyperamylasemia was proved to be from other cause, rather than AP, were excluded.

Patients were classified as SAP if organ failure was present for more than 48 hours. In accordance to the Marshall Scoring System, organ failure includes at least one of the following features: (i) Respiratory failure, defined as PO2/FIO2 ≤ 300 mmHg; (ii) renal failure, defined as serum creatinine level ≥ 1.9 mg/dl; and (iii) shock, defined as systolic blood pressure < 90 mmHg and unresponsive to fluid therapy.

As a local complication, PNec was diagnosed by CECT when there was lack of enhancement of pancreatic parenchyma after contrast infusion.

For each patient, all CRP determinations obtained during the first 24 hours after hospital admission were collected and only the greatest level of those was considered for analysis. These CRP determinations were obtained using the standard technique at the hospital’s laboratory (Dimension Vista System, Flex reagent cartridge, Siemens Healthcare Diagnostics Products, Germany) and expressed in mg/l.

BISAP score was determined according to what has been previously published.

2.3. Primary exposures and primary outcome

Primary exposures were CRP level and BISAP score in the first 24 hours after hospital admission. Primary outcome was IM, which referred to death occurring from AP or its complications (inflammatory, septic, morphological or others) during index hospital stay.

2.4. Statistical analysis

Categorical variables were presented as frequencies and percentages and continuous variables as median and inter-quartile range (percentile 25–percentile 75) or range (minimum–maximum). Missing data were not replaced or estimated.

Univariable analysis used nonparametric tests (Chi-square, Fisher’s Exact, Mann-Whitney U) due to the existence of outliers and skewed distributions. Logistic regression models were used to evaluate the prognostic accuracy of CRP24 and BISAP for IM with odds ratios (ORs) being calculated after cross-validation. Discriminative ability was assessed by the area under the receiver–operating characteristic curve (AUCs) and comparison between AUCs was made using the method described by DeLong et al. To compensate for possible shortcomings of AUC analysis in quantifying the added value of a biomarker to an existing test, continuous net reclassification improvement (NRI) and integrated discrimination improvement (IDI) parameters were also calculated.

All statistical tests were two-sided and P < 0.05 was considered statistically significant. All analyses were performed with IBM SPSS Statistics, Version 19.0 (IBM Corp., North Castle, New York, USA) and Stata/IC 12.0 (Statacorp. LP, College Station, TX, USA).

3. Results

3.1. Patients’ characteristics

A total of 299 patients were initially included. Of this set, only 134 patients (44.8%) had complete data on CRP24, BISAP, and in-hospital final vital status and were subsequently considered.

Median age was 64 years (range, 13–96 years), with 80 men (59.7%). Biliary lithiasis was the most frequent identifiable cause of AP with 59 patients (44.0%). Of a total of 70 patients (52.2%) with complete data on organ failure parameters, 9 (12.9%) developed organ failure for more than 48 hours and were classified as having SAP. CECT was performed in 91 patients (67.9%) and in 24 of those (26.4%) pancreatic necrosis was found. Median day for CECT performance was the fourth day of hospital stay (range, 1–26 days). From the 70 patients with Marshall score evaluation, 51 (72.9%) underwent CECT; from the 9 patients with SAP, 4 (44.4%) were diagnosed with pancreatic necrosis. Median length of hospital stay was 9 days (range, 1–80 days). Nine patients (6.7%) died during index hospital stay. Median time to death was 15 days (range, 1–60 days).

3.2. CRP24 prognostic accuracy for IM

Median overall CRP24 level was 104.4 (inter-quartile range, 29.2–191.2 mg/l) and its distribution by IM status is shown in Fig. 1. Median CRP24 level was higher in patients who died during index hospital stay (197.2 vs. 100.2, p = 0.003). CRP24 univariable OR for IM was 1.11 (95% CI, 1.04–1.17) and corresponding AUC was 0.80 (95% CI, 0.65–0.95). Analysis of the coordinate points of the receiver–operating characteristic curve showed that, from the 46 patients with a CRP24 level
lower than 60 mg/l, none died (p = 0.027). Additionally, from the 9 patients with SAP, only one (11.1%) had a CRP24 level lower than 60 mg/l. This CRP24 cutoff point yielded the following sensitivity, specificity, negative predictive value, and positive predictive value for IM: 100% (95% CI, 66.4–100%), 36.8% (95% CI, 28.4–45.9%), 100% (95% CI, 92.3–100%), and 10.0% (95% CI, 4.8–18.5%), respectively.

### 3.3 BISAP prognostic accuracy for IM

The distribution of patients by BISAP categories is shown in Fig. 2. Twenty-three patients (17%) had a BISAP score equal or greater than 3. BISAP univariable OR for IM was 2.27 (95% CI, 1.37–3.77) and corresponding AUC was 0.77 (95% CI, 0.59–0.95).

### 3.4 BISAP plus CRP24 model prognostic accuracy for IM

After cross-validation, BISAP plus CRP24 model ORs for IM were 1.77 (95% CI, 1.05–3.00) for BISAP and 1.09 (95% CI, 1.02–1.16) for CRP24; corresponding AUC was 0.81 (95% CI, 0.65–0.97). AUCs of BISAP alone and BISAP plus CRP24 model were not significantly different (Fig. 3: P = 0.62).

Statistics of BISAP prognostic accuracy for IM improvement with the addition of CRP24 are summarized in Table 1. The overall reclassification of patients (NRI) was mainly due to the reclassification of survivors (non-events), as absolute NRI\textsubscript{non-events} was greater than NRI\textsubscript{events}. In fact, the NRI\textsubscript{non-events} showed a significant change (42.4%; 95% CI, 24.9–59.9%) which resulted in a positive overall NRI (31.3%; 95% CI, −36.4 to 98.9%), but the ID\textsubscript{non-events} was negligible, with a 95% CI straddling zero (0.004; 95% CI, −0.007 to 0.014). This means that the addition of CRP24 to BISAP reduced the calculated risk of IM in about 42% of patients who survived, albeit the overall effect was not statistically significant.

### 4. Discussion

In this study, we found that CRP24 may be a useful biochemical marker for the early risk assessment of patients with AP.

CRP24 showed good individual prognostic accuracy for IM in AP. Moreover, the evaluation of a possible cutoff point with clinical relevance revealed that 60 mg/l warranted a negative predictive value of 100%, meaning that patients with AP and a CRP24 level lower than that cutoff point were not at risk of dying from AP or its complications during the following hospital stay. The low prevalence of IM in
Table 1  Statistics of BISAP’s prognostic accuracy for in-hospital mortality in acute pancreatitis improvement with the addition of CRP24.

| Statistics | Coefficient (95% CI) |
|------------|----------------------|
| **AUC**    |                      |
| BISAP      | 0.77 (0.59–0.95)    |
| BISAP + CRP24 | 0.81 (0.65–0.97) |
| **NRI (%)**|                      |
| NRIevents  | −11.1 (−76.4 to 54.2) |
| NRInonevents | 42.4 (24.9–59.9) |
| NRIb        | 31.3 (−36.4 to 98.9) |
| **IDI**    |                      |
| IDIevents  | 0.029 (−0.115 to 0.173) |
| IDInonevents | 0.004 (−0.007 to 0.014) |
| IDIb        | 0.033 (−0.112 to 0.177) |

CI, confidence interval; AUC, area under receiver–operating curve; BISAP, Bedside Index for Severity in Acute Pancreatitis; CRP24, C-reactive protein at 24 hours after hospital admission; NRI, continuous net reclassification improvement; IDI, integrated discrimination improvement; Events, patients that died; Nonevents, patients that survived.

a NRI equals NRIevents plus NRInonevents.
b IDI equals IDIevents plus IDInonevents.

this population-based study may have precluded the determination of a cutoff point with a high positive predictive value.19

Adding CRP24 to BISAP may have represented an improvement in prognostic accuracy for IM in AP; in this regard, the real gain may have been due to the reclassification of patients at low risk to die from AP or its complications during index hospital stay. Despite these observed tendencies, statistical significance was not achieved.

Overall, this study emphasizes the role of CRP24 in the early risk assessment of patients with AP individually and in combination with BISAP. These results underline the possible advantages of combining simple and accessible tools for clinicians to perform a more reliable early risk assessment of patients with AP, as it has been outlined elsewhere20; this may be done not only by selecting patients at high risk for complications, but also by identifying those within the low risk subgroup that most probably will not develop complications. This approach may help specific institutional policies on AP by improving efficiency in patient management and resources utilization.

There were some methodological limitations to this study. First, this was a retrospective analysis of prospectively collected data from a single center and may have been prone to selection bias and limited generalization. Second, missing CRP24 determinations, which made the final sample size smaller, might have impacted negatively the final prognostic accuracy results for the BISAP plus CRP24 model. The methodological strengths of this study were mainly the community based and consecutive admission of patients and the additional use of NRI and IDI to assess the prognostic performance of BISAP plus CRP24 model. In the future, prospective and properly powered studies should address CRP24 prognostic accuracy in AP and the possibility of combining it with BISAP or other early risk assessment tools available for patients with AP.

In conclusion, there seems to be a role for CRP24 in the early risk assessment of patients with AP, especially by identifying lowest risk patients.

Conflicts of interest

None declared.

Ethical disclosures

Protection of human and animal subjects. The authors declare that the procedures followed were in accordance with the regulations of the relevant clinical research ethics committee and with those of the Code of Ethics of the World Medical Association (Declaration of Helsinki).

Confidentiality of data. The authors declare that they have followed the protocols of their work center on the publication of patient data.

Right to privacy and informed consent. The authors have obtained the written informed consent of the patients or subjects mentioned in the article. The corresponding author is in possession of this document.

References

1. Yadav D, Lowenfels AB. Trends in the epidemiology of the first attack of acute pancreatitis: a systematic review. Pancreas. 2006;33:323–30.
2. Spanier BW, Djikgraaf MG, Brun AM. Epidemiology, aetiology and outcome of acute and chronic pancreatitis: an update. Best Pract Res Clin Gastroenterol. 2008;22:45–63.
3. Swaroop VS, Chari ST, Clain JE. Severe acute pancreatitis. J Am Med Assoc. 2004;291.
4. Sekimoto M, Takada T, Kawarada Y, Hirata K, Mayumi T, Yoshida M, et al. JPN Guidelines for the management of acute pancreatitis: epidemiology, etiology, natural history, and outcome predictors in acute pancreatitis. J Hepatobiliary Pancreat Surg. 2006;13:10–24.
5. Lowenfels AB, Maisonneuve P, Sullivan T. The changing character of acute pancreatitis: epidemiology, etiology, and prognosis. Curr Gastroenterol Rep. 2009;11:97–103.
6. Schütte K, Malfertheiner P. Markers for predicting severity and progression of acute pancreatitis. Best Pract Res Clin Gastroenterol. 2008;22:75–90.
7. Werner J, Hartwig W, Uhl W, Müller C, Büchler MW. Useful markers for predicting severity and monitoring progression of acute pancreatitis. Pancreatology. 2003;3:115–27.
8. Mayer AD, McMahon MJ, Bowen M, Cooper EH. C reactive protein: an aid to assessment and monitoring of acute pancreatitis. J Clin Pathol. 1984;37:207–11.
9. Pongprasobchai S, Jianjaroonwong V, Charatcharoenwitthaya P, Komoltri C, Tanwanadee T, Leelakusolvong S, et al. Erythrocyte sedimentation rate and C-reactive protein for the prediction of severity of acute pancreatitis. Pancreas. 2010;39:1226–30.
10. Wu BU, Johannes RS, Sun X, Tabak Y, Conwell DL, Banks PA. The early prediction of mortality in acute pancreatitis: a large population-based study. Gut. 2008;57:1698–703.
11. Papachristou GI, Muddana V, Yadav D, O’Connell M, Sanders MK, Slivka A, et al. Comparison of BISAP, Ranson’s, APACHE-II, and CTSI scores in predicting organ failure, complications,
and mortality in acute pancreatitis. Am J Gastroenterol. 2010;105:435–41.

12. Park JY, Jeon TJ, Ha TH, Hwang JT, Sinn DH, Oh TH, et al. Bedside index for severity in acute pancreatitis: comparison with other scoring systems in predicting severity and organ failure. Hepatobiliary Pancreat Dis Int. 2013;12:645–50.

13. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Br Med J. 2007;335:806–8.

14. Acute Pancreatitis Classification Working Group. Revision of the Atlanta Classification of Acute Pancreatitis. April 9, 2008. [accessed 15.11.11] Available at: http://pancreasclub.com/wp-content/uploads/2011/11/AtlantaClassification.pdf.

15. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982;143:29–36.

16. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver-operating characteristic curves: a nonparametric approach. Biometrics. 1988;44:837–45.

17. Pickering JW, Endre Z. New metrics for assessing diagnostic potential of candidate biomarkers. Clin J Am Soc Nephrol. 2012;7:1355–64.

18. Pencina MJ, D’Agostino RB, Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med. 2011;30:11–21.

19. Brenner H, Gefeller O. Variation of sensitivity, specificity, likelihood ratios and predictive values with disease prevalence. Stat Med. 1997;16:981–91.

20. Mounzer R, Langmead CJ, Wu BU, Evans AC, Bishehsari F, Muddana V, et al. Comparison of existing clinical scoring systems to predict persistent organ failure in patients with acute pancreatitis. Gastroenterology. 2012;142:1476–82.